1,4-dihydroxy-2-naphthoic acid induces apoptosis in human keratinocyte: Potential application for psoriasis treatment

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Mok, Chong Fai ^a   Xie, Chuan Ming ^a   Sham, Kathy Wai Yan ^a   Lin, Zhi Xiu ^b   Cheng, Christopher Hon Ki ^a,b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROXY 2 NAPHTHOIC ACID; 2 NAPHTHOIC ACID DERIVATIVE; ANTIPSORIASIS AGENT; CASPASE; DITHRANOL; INTERLEUKIN 1ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CYTOKINE RELEASE; CYTOTOXICITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PSORIASIS; RUBIA CORDIFOLIA;

EID: 84877278746     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/792840     Document Type: Article

References (80)

1. Afifi T., de Gannes G., Huang C., Zhou Y., Topical therapies for psoriasis: evidence-based review. Canadian Family Physician 2005 51 519 525 2-s2.0-17244378287 (Pubitemid 40528840)
2. Griffiths C. E., Barker J. N., Pathogenesis and clinical features of psoriasis. The Lancet 2007 370 9583 263 271 2-s2.0-34447539622 10.1016/S0140-6736(07)61128-3 (Pubitemid 47069537)
3. Traub M., Marshall K., Psoriasis-pathophysiology, conventional, and alternative approaches to treatment. Alternative Medicine Review 2007 12 4 319 330 2-s2.0-37549028062
4. Linden K. G., Weinstein G. D., Psoriasis: current perspectives with an emphasis on treatment. The American Journal of Medicine 1999 107 6 595 605 2-s2.0-0032786879 10.1016/S0002-9343(99)00284-3
5. Miller D. W., Feldman S. R., Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opinion on Pharmacotherapy 2006 7 2 157 167 2-s2.0-33144473657 10.1517/14656566.7.2.157 (Pubitemid 43263255)
6. Sizto S., Bansback N., Feldman S. R., Willian M. K., Anis A. H., Economic evaluation of systemic therapies for moderate to severe psoriasis. The British Journal of Dermatology 2009 160 6 1264 1272 2-s2.0-66149110602 10.1111/j.1365-2133.2008.08962.x
7. Yu X. J., Li C. Y., Dai H. Y., Cai D. X., Wang K. Y., Xu Y. H., Chen L. M., Zhou C. L., Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Experimental and Molecular Pathology 2007 83 3 413 418 2-s2.0-36148934536 10.1016/j.yexmp.2007.05.002 (Pubitemid 350103561)
8. Kharaeva Z., Gostova E., de Luca C., Raskovic D., Korkina L., Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition 2009 25 3 295 302 2-s2.0-60149086951 10.1016/j.nut.2008.08.015
9. Heenen M., Simonart T., Apoptosis in psoriatic epidermis. Journal of Cutaneous Pathology 2008 35 3 346 2-s2.0-38649122700 10.1111/j.1600-0560.2007. 00795.x (Pubitemid 351171242)
10. Laporte M., Galand P., Fokan D., De Graef C., Heenen M., Apoptosis in established and healing psoriasis. Dermatology 2000 200 4 314 316 2-s2.0-0033921950 (Pubitemid 30451579)
11. Boehm I., Apoptosis in physiological and pathological skin: implications for therapy. Current Molecular Medicine 2006 6 4 375 394 2-s2.0-33744802411 10.2174/156652406777435390 (Pubitemid 43834251)
12. Tse W. P., Che C. T., Liu K., Lin Z. X., Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. Journal of Ethnopharmacology 2006 108 1 133 141 2-s2.0-33749337643 10.1016/j.jep.2006.04.023 (Pubitemid 44498993)
13. Tse T. W., Use of common Chinese herbs in the treatment of psoriasis. Clinical and Experimental Dermatology 2003 28 5 469 475 2-s2.0-0042911964 10.1046/j.1365-2230.2003.01322.x (Pubitemid 37100542)
14. Koo J., Arain S., Traditional chinese medicine for the treatment of dermatologic disorders. Archives of Dermatology 1998 134 11 1388 1393 2-s2.0-0031785570 (Pubitemid 28543654)
15. May B. H., Zhang A. L., Zhou W., Oral herbal medicines for psoriasis: a review of clinical studies. The Chinese Journal of Integrative Medicine 2012 18 3 172 178
16. Li N., Li Y. Q., Li H. Y., Guo W., Bai Y. P., Efficacy of externally applied Chinese herbal drugs in treating psoriasis: a systematic review. The Chinese Journal of Integrative Medicine 2012 18 3 222 229
17. Zhang H., Gu J., Progress of experimental study on treatment of psoriasis by Chinese medicinal monomer and single or compound recipe in Chinese Materia Medica. The Chinese Journal of Integrative Medicine 2007 13 4 312 316 2-s2.0-37549035861 10.1007/s11655-007-0312-5
18. Koo J., Desai R., Traditional Chinese medicine in dermatology. Dermatologic Therapy 2003 16 2 98 105 2-s2.0-0041671045 10.1046/j.1529-8019. 2003.01617.x (Pubitemid 36918064)
19. Song P., Yan Z. F., Xu X., Clinical observation on effect of compound E-bei ointment in treating plaque psoriasis. Chinese Journal of Integrated Traditional and Western Medicine 2007 27 4 352 354 2-s2.0-58149093265
20. Tse W. P., Cheng C. H. K., Che C. T., Zhao M., Lin Z. X., Induction of apoptosis underlies the Radix Rubiae-mediated anti-proliferative action on human epidermal keratinocytes: implications for psoriasis treatment. International Journal of Molecular Medicine 2007 20 5 663 672 2-s2.0-38449102690
21. Lin Z. X., Jiao B. W., Che C. T., Zuo Z., Mok C. F., Zhao M., Ho W. K. K., Tse W. P., Lam K. Y., Fan R. Q., Yang Z. J., Cheng C. H. K., Ethyl acetate fraction of the root of Rubia cordifolia L. inhibits keratinocyte proliferation in vitro and promotes keratinocyte differentiation in vivo: potential application for psoriasis treatment. Phytotherapy Research 2010 24 7 1056 1064 2-s2.0-77954484937 10.1002/ptr.3079
22. Lowes M. A., Bowcock A. M., Krueger J. G., Pathogenesis and therapy of psoriasis. Nature 2007 445 7130 866 873 2-s2.0-33847279025 10.1038/nature05663
23. Zenz R., Eferl R., Kenner L., Florin L., Hummerich L., Mehic D., Scheuch H., Angel P., Tschachler E., Wagner E. F., Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005 437 7057 369 375 2-s2.0-25144497098 10.1038/nature03963 (Pubitemid 41613493)
24. Liu Y., Krueger J. G., Bowcock A. M., Psoriasis: genetic associations and immune system changes. Genes and Immunity 2007 8 1 1 12 2-s2.0-33846500207 10.1038/sj.gene.6364351 (Pubitemid 46158098)
25. Kanda N., Watanabe S., Suppressive effects of antimycotics on tumor necrosis factor- α -induced CCL27, CCL2, and CCL5 production in human keratinocytes. Biochemical Pharmacology 2006 72 4 463 473 2-s2.0-33745935754 10.1016/j.bcp.2006.05.001 (Pubitemid 44061743)
26. Zhang M., Zhu L., Feng Y., Yang Y., Liu L., Ran Y., Effects of acitretin on proliferative inhibition and RANTES production of HaCaT cells. Archives of Dermatological Research 2008 300 10 575 581 2-s2.0-55049123680 10.1007/s00403-008-0872-z
27. Jiang C. K., Magnaldo T., Ohtsuki M., Freedberg I. M., Bernerd F., Blumenberg M., Epidermal growth factor and transforming growth factor α specifically induce the activation- and hyperproliferation-associated keratins 6 and 16. Proceedings of the National Academy of Sciences of the United States of America 1993 90 14 6786 6790 2-s2.0-0027323132 (Pubitemid 23207298)
28. Chen G., McCormick T. S., Hammerberg C., Ryder-Diggs S., Stevens S. R., Cooper K. D., Basal keratinocytes from uninvolved psoriatic skin exhibit accelerated spreading and focal adhesion kinase responsiveness to fibronectin. Journal of Investigative Dermatology 2001 117 6 1538 1545 2-s2.0-0035674148 10.1046/j.0022-202x.2001.01535.x (Pubitemid 34032785)
29. Danilenko D. M., Preclinical models of psoriasis. Veterinary Pathology 2008 45 4 563 575 2-s2.0-54749085848 10.1354/vp.45-4-563
30. Boehncke W. H., Schön M. P., Animal models of psoriasis. Clinics in Dermatology 2007 25 6 596 605 2-s2.0-36048998107 10.1016/j.clindermatol.2007.08. 014 (Pubitemid 350087606)
31. Lin J., Liu X., Bao Y., Hou S., An L., Lin X., Effects of isocamptothecin, a novel camptothecin analogue, on proliferation, apoptosis and telomerase activity in HaCaT cells. Experimental Dermatology 2008 17 6 530 536 2-s2.0-43449090712 10.1111/j.1600-0625.2007.00674.x (Pubitemid 351663282)
32. Cai Y., Sun M., Xing J., Corke H., Antioxidant phenolic constituents in roots of Rheum officinale and Rubia cordifolia: structure-radical scavenginq activity relationships. Journal of Agricultural and Food Chemistry 2004 52 26 7884 7890 2-s2.0-11144241260 (Pubitemid 40053671)
33. Singh R., Chauhan S. M., 9,10-Anthraquinones and other biologically active compounds from the genus Rubia. Chemistry & biodiversity 2004 1 9 1241 1264 2-s2.0-27444442274 10.1002/cbdv.200490088
34. Lebwohl M., Ali S., Treatment of psoriasis. Part 1. Topical therapy and phototherapy. Journal of the American Academy of Dermatology 2001 45 4 487 502 2-s2.0-0034805313 10.1067/mjd.2001.117046 (Pubitemid 32917240)
35. Menter A., Griffiths C. E., Current and future management of psoriasis. The Lancet 2007 370 9583 272 284 2-s2.0-34447547568 10.1016/S0140-6736(07)61129- 5 (Pubitemid 47071926)
36. McBride S. R., Walker P., Reynolds N. J., Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. The British Journal of Dermatology 2003 149 6 1259 1265 2-s2.0-0347986600 10.1111/j.1365-2133.2003.05653.x (Pubitemid 38058103)
37. Welss T., Basketter D. A., Schröder K. R., In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicology in Vitro 2004 18 3 231 243 2-s2.0-1642318502 10.1016/j.tiv.2003.09.009 (Pubitemid 38376355)
38. Cotovio J., Grandidier M. H., Portes P., Roguet R., Rubinstenn G., The in vitro acute skin irritation of chemicals: optimisation of the EPISKIN prediction model within the framework of the ECVAM validation process. ATLA Alternatives to Laboratory Animals 2005 33 4 329 349 2-s2.0-24944481113 (Pubitemid 41330270)
39. Sanchez L., Mitjans M., Infante M. R., Vinardell M. P., Determination of interleukin-1 α in human NCTC 2544 keratinocyte cells as a predictor of skin irritation from lysine-based surfactants. Toxicology Letters 2006 167 1 40 46 2-s2.0-33749649848 10.1016/j.toxlet.2006.08.006 (Pubitemid 44548276)
40. Gibbs S., In vitro irritation models and immune reactions. Skin Pharmacology and Physiology 2009 22 2 103 113 2-s2.0-59649124769 10.1159/000178869
41. Roelofzen J. H. J., Aben K. K. H., Khawar A. J. M., Van De Kerkhof P. C. M., Kiemeney L. A. L. M., Van Der Valk P. G. M., Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders. The European Journal of Dermatology 2007 17 5 416 421 2-s2.0-34548719840 10.1684/ejd.2007.0240 (Pubitemid 47425909)
42. McGill A., Frank A., Emmett N., Turnbull D. M., Birch-Machin M. A., Reynolds N. J., The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB Journal 2005 19 8 1012 1014 2-s2.0-20444447706 10.1096/fj.04-2664fje (Pubitemid 40827735)
43. Draize J. H., Woodard G., Calvery H. O., Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. Journal of Pharmacology and Experimental Therapeutics 1944 82 3 377 390
44. Mizumoto N., Mummert M. E., Shalhevet D., Takashima A., Keratinocyte ATP release assay for testing skin-irritating potentials of structurally diverse chemicals. Journal of Investigative Dermatology 2003 121 5 1066 1072 2-s2.0-0242658509 10.1046/j.1523-1747.2003.12558.x (Pubitemid 37430975)
45. Garthoff B., Alternatives to animal experimentation: the regulatory background. Toxicology and Applied Pharmacology 2005 207 2, supplement S388 S392 2-s2.0-24644513055 10.1016/j.taap.2005.02.024 (Pubitemid 41265539)
46. Eun H. C., Suh D. H., Comprehensive outlook of in vitro tests for assessing skin irritancy as alternatives to Draize tests. Journal of Dermatological Science 2000 24 2 77 91 2-s2.0-0033752815 10.1016/S0923-1811(00) 00093-1
47. Kodithala K., Hopfinger A. J., Thompson E. D., Robinson M. K., Prediction of skin irritation from organic chemicals using membrane-interaction QSAR analysis. Toxicological Sciences 2002 66 2 336 346 2-s2.0-0036212084 10.1093/toxsci/66.2.336 (Pubitemid 34285129)
48. Lee J. K., Kim D. B., Kim J. I., Kim P. Y., In vitro cytotoxicity tests on cultured human skin fibroblasts to predict skin irritation potential of surfactants. Toxicology in Vitro 2000 14 4 345 349 2-s2.0-0033921110 10.1016/S0887-2333(00)00028-X (Pubitemid 30440602)
49. Korting H. C., Herzinger T., Hartinger A., Kerscher M., Angerpointner T., Maibach H. I., Discrimination of the irritancy potential of surfactants in vitro by two cytotoxicity assays using normal human keratinocytes, HaCaT cells and 3T3 mouse fibroblasts: correlation with in vivo data from a soap chamber assay. Journal of Dermatological Science 1994 7 2 119 129 2-s2.0-0028335894 10.1016/0923-1811(94)90085-X
50. Osborne R., Perkins M. A., An approach for development of alternative test methods based on mechanisms of skin irritation. Food and Chemical Toxicology 1994 32 2 133 142 2-s2.0-0028344686 10.1016/0278-6915(94)90174-0 (Pubitemid 24131131)
51. Wilhelm K. P., Böttjer B., Siegers C. P., Quantitative assessment of primary skin irritants in vitro in a cytotoxicity model: comparison with in vivo human irritation tests. The British Journal of Dermatology 2001 145 5 709 715 2-s2.0-0035166895 10.1046/j.1365-2133.2001.04497.x (Pubitemid 33078340)
52. Sanchez L., Mitjans M., Infante M. R., Vinardell M. P., Potential irritation of lysine derivative surfactants by hemolysis and HaCaT cell viability. Toxicology Letters 2006 161 1 53 60 2-s2.0-28844468793 10.1016/j.toxlet.2005.07.015 (Pubitemid 41770876)
53. Martinez V., Corsini E., Mitjans M., Pinazo A., Vinardell M. P., Evaluation of eye and skin irritation of arginine-derivative surfactants using different in vitro endpoints as alternatives to the in vivo assays. Toxicology Letters 2006 164 3 259 267 2-s2.0-33646866349 10.1016/j.toxlet.2006.01.005 (Pubitemid 43786337)
54. Parodi A., Sanguineti R., Catalano M., Penco S., Pronzato M. A., Scanarotti C., Bassi A. M., A comparative study of leukaemia inhibitory factor and interleukin-1 α intracellular content in a human keratinocyte cell line after exposure to cosmetic fragrances and sodium dodecyl sulphate. Toxicology Letters 2010 192 2 101 107 2-s2.0-73749085581 10.1016/j.toxlet.2009. 10.013
55. Corsini E., Primavera A., Marinovich M., Galli C. L., Selective induction of cell-associated interleukin-1 α in murine keratinocytes by chemical allergens. Toxicology 1998 129 2-3 193 200 2-s2.0-0032555773 10.1016/S0300-483X(98)00088-2 (Pubitemid 29023147)
56. Zuang V., Alonso M. A., Botham P. A., Eskes C., Fentem J., Liebsch M., van De Sandt J. J. M., Skin irritation and corrosion. Alternatives to Laboratory Animals 2005 33 1 35 46 2-s2.0-22844432717 (Pubitemid 41039555)
57. Luo D., Min W., Wu D., IL-1 α and ATP mRNA expression after ultraviolet irradiation in human keratinocyte original-SCC 12F cells. The Chinese Medical Journal 2004 117 4 581 585 2-s2.0-2342557936 (Pubitemid 38579081)
58. Martin S. J., Reutelingsperger C. P. M., McGahon A. J., Rader J. A., Van Schie R. C. A. A., LaFace D. M., Green D. R., Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Journal of Experimental Medicine 1995 182 5 1545 1556 2-s2.0-0028800947 10.1084/jem.182.5.1545
59. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S., A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998 391 6662 43 50 2-s2.0-0031888955 10.1038/34112 (Pubitemid 28079208)
60. Ihara T., Yamamoto T., Sugamata M., Okumura H., Ueno Y., The process of ultrastructural changes from nuclei to apoptotic body. Virchows Archiv 1998 433 5 443 447 2-s2.0-0031784094 10.1007/s004280050272 (Pubitemid 28522033)
61. Adhami V. M., Aziz M. H., Reagan-Shaw S. R., Nihal M., Mukhtar H., Ahmad N., Sanguinarine causes cell cyle blockade and apoptosis of human prostate carcinoma cells via modulation of cylin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Molecular Cancer Therapeutics 2004 3 8 933 940 2-s2.0-4444220152 (Pubitemid 39199588)
62. Chow S. K. Y., Chan J. Y. W., Fung K. P., Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. Journal of Cellular Biochemistry 2004 93 1 173 187 2-s2.0-16644398131 10.1002/jcb.20102
63. Gartel A. L., Tyner A. L., The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Molecular cancer therapeutics 2002 1 8 639 649 2-s2.0-0036594890
64. Jada S. R., Matthews C., Saad M. S., Hamzah A. S., Lajis N. H., Stevens M. F. G., Stanslas J., Benzylidene derivatives of andrographolide inhibit growth of breast and colon cancer cells in vitro by inducing G1 arrest and apoptosis. The British Journal of Pharmacology 2008 155 5 641 654 2-s2.0-54949147613 10.1038/bjp.2008.368
65. Mihara M., Shintani S., Nakashiro K. I., Hamakawa H., Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. Oral Oncology 2003 39 1 49 55 2-s2.0-0037210732 10.1016/S1368-8375(02)00019-2 (Pubitemid 35379818)
66. Bata-Csorgo Z., Hammerberg C., Voorhees J. J., Cooper K. D., Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. Journal of Experimental Medicine 1993 178 4 1271 1281 2-s2.0-0027248633 (Pubitemid 23277360)
67. Farkas A., Kemeny L., Szell M., Dobozy A., Bata-Csorgo Z., Ethanol and acetone stimulate the proliferation of HaCaT keratinocytes: the possible role of alcohol in exacerbating psoriasis. Archives of Dermatological Research 2003 295 2 56 62 2-s2.0-0038389325 10.1007/s00403-003-0399-2 (Pubitemid 36791724)
68. Igney F. H., Krammer P. H., Death and anti-death: tumour resistance to apoptosis. Nature Reviews Cancer 2002 2 4 277 288 2-s2.0-0036547417 (Pubitemid 37328781)
69. Zimmermann K. C., Green D. R., How cells die: apoptosis pathways. Journal of Allergy and Clinical Immunology 2001 108 4 S99 S103 2-s2.0-0034780177 10.1067/mai.2001.117819 (Pubitemid 32978004)
70. Gukovskaya A. S., Pandol S. J., Cell death pathways in pancreatitis and pancreatic cancer. Pancreatology 2004 4 6 567 586 2-s2.0-11844301338 10.1159/000082182 (Pubitemid 40091409)
71. Saelens X., Festjens N., Vande Walle L., Van Gurp M., Van Loo G., Vandenabeele P., Toxic proteins released from mitochondria in cell death. Oncogene 2004 23 16 2861 2874 2-s2.0-2342471409 10.1038/sj.onc.1207523 (Pubitemid 38638848)
72. Vermeulen K., van Bockstaele D. R., Berneman Z. N., Apoptosis: mechanisms and relevance in cancer. Annals of Hematology 2005 84 10 627 639 2-s2.0-27644542306 10.1007/s00277-005-1065-x (Pubitemid 41554237)
73. Düssmann H., Kögel D., Rehm M., Prehn J. H. M., Mitochondrial membrane permeabilization and superoxide production during apoptosis: a single-cell analysis. Journal of Biological Chemistry 2003 278 15 12645 12649 2-s2.0-0142049202 10.1074/jbc.M210826200 (Pubitemid 36800024)
74. Lorenzo H. K., Susin S. A., Penninger J., Kroemer G., Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death and Differentiation 1999 6 6 516 524 2-s2.0-0033010612 (Pubitemid 29292107)
75. Huang K. J., Ku C. C., Lehman I. R., Endonuclease G: a role for the enzyme in recombination and cellular proliferation. Proceedings of the National Academy of Sciences of the United States of America 2006 103 24 8995 9000 2-s2.0-33745171416 10.1073/pnas.0603445103 (Pubitemid 43902522)
76. Li L. Y., Luo L., Wang X. D., Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001 412 6842 95 99 2-s2.0-0035811496 10.1038/35083620 (Pubitemid 32851517)
77. Zhang W., Zhang C., Narayani N., Du C., Balaji K. C., Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in LNCaP prostate cancer cells. Cancer Letters 2007 255 1 127 134 2-s2.0-34547689201 10.1016/j.canlet.2007.04.006 (Pubitemid 47212614)
78. Carey W., Glazer S., Gottlieb A. B., Lebwohl M., Leonardi C., Menter A., Papp K., Rundle A. C., Toth D., Relapse, rebound, and psoriasis adverse events: an advisory group report. Journal of the American Academy of Dermatology 2006 54 4, supplement 1 S171 S181 2-s2.0-32544441226 10.1016/j.jaad.2005.10.029 (Pubitemid 43238300)
79. Endzweig-Gribetz C. H., Brady C., Lynde C., Sibbald D., Lebwohl M., Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies. Journal of Cutaneous Medicine and Surgery 2002 6 3 12 16 2-s2.0-0036348498
80. Koo J., Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. Journal of the American Academy of Dermatology 1999 41 3, part 2 S25 S28 2-s2.0-0032835816 (Pubitemid 29416465)